Gene therapy trial participant Aiden Moore-Van De Rostyne
Aiden Moore-Van De Rostyne, 16, of Walla Walla, Washington, plays with her 6-year-old brother Benson Moore. Aiden was born legally blind because of a gene mutation and is now participating in a clinical trial for an experimental gene therapy that is designed to provide a working copy of the mutated gene. (Courtesy)
Gene therapy trial participant Aiden Moore-Van De Rostyne
Aiden Moore-Van De Rostyne, 16, of Walla Walla, Washington, with her mother, Eliza Van De Rostyne. (Courtesy of Eliza Van De Rostyne)
Paul Yang, M.D., Ph.D. (OHSU)
Video: Snowflakes
Eliza Van De Rostyne recorded this video with her phone when her daughter, Aiden Moore-Van De Rostyne, 16, of Walla Walla, Washington, unexpectedly saw snowflakes for the first time in January 2023. Aiden was born legally blind because of a GUYCY2D gene mutation, and received an experimental gene therapy in April 2022 as a clinical trial participant at Oregon Health & Science University in Portland, Oregon. Aiden is one of the first 15 people in the United States to receive Atsena Therapeutics’ ATSN-101 experimental treatment for Leber congenital amaurosis. (Courtesy of Eliza Van De Rostyne)
Arpiar Saunders, Ph.D.
Arpiar “Arpy” Saunders, Ph.D., assistant scientist in OHSU’s Vollum Institute, is one of three researchers nationwide named as Rising Stars by One Mind, a nonprofit organization focused on neuropsychiatric brain research. (OHSU/Christine Torres Hicks)
Apriar Saunders and the Saunders Lab team (OHSU)
OHSU neuroscientist earns award to advance schizophrenia research
Dale and Julie Burghardt
The Burghardts’ inspiration for the center came from their family’s own personal experience, with both Julie and their now 5-year-old grandson, Harrison, managing food allergies. (Photo courtesy of The Burghardts)